Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | L194F |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 L194F lies within the DNA binding domain of the Tp53 protein (UniProt.org). L194F confers a loss of function to the Tp53 protein, as demonstrated by decreased Tp53 transactivation activity and decreased binding to Bcl2 in cell culture (PMID: 16443602). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon6 TP53 L194F TP53 mutant TP53 inact mut TP53 L194F |
Transcript | NM_000546.6 |
gDNA | chr17:g.7674951G>A |
cDNA | c.580C>T |
Protein | p.L194F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126113 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7674951G>A | c.580C>T | p.L194F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 L194F | breast cancer | sensitive | Ganetespib | Preclinical - Cell culture | Actionable | In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PMID: 26009011). | 26009011 |
TP53 L194F | breast cancer | sensitive | Tanespimycin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 |
TP53 L194F | breast cancer | sensitive | Vorinostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 |
TP53 L194F | breast cancer | sensitive | Tanespimycin + Vorinostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 |